Version history

{
  "description": "## Mechanistic Overview\nClosed-loop transcranial focused ultrasound with 40Hz gamma entrainment to restore hippocampal-cortical connectivity in early MCI starts from the claim that modulating PVALB within the disease context of Alzheimer's disease can redirect a disease-relevant process. The original description reads: \"**Molecular Mechanism and Rationale** The proposed closed-loop transcranial focused ultrasound (tFUS) with 40Hz gamma entrainment targets a fundamental pathophysiological circuit disruption in early Alzheimer's disease: the selective vulnerability and dysfunction of parvalbumin-positive (PV+) fast-spiking interneurons in the CA1 hippocampal subfield. These GABAergic interneurons, encoded by the PVALB gene, serve as the primary pacemakers for gamma oscillations (30-80 Hz) through their capacity for rapid perisomatic inhibition of CA1 pyramidal neurons. In healthy brains, PV+ interneurons generate synchronized 40Hz gamma rhythms that coordinate hippocampal-cortical information transfer, enabling memory encoding and retrieval processes. The molecular cascade begins when tFUS delivers precisely calibrated 40Hz acoustic pulses directly to CA1 regions, generating mechanical forces that activate voltage-gated sodium channels, particularly Nav1.1 (SCN1A), which are highly expressed on PV+ interneuron axon initial segments. This mechanostimulation triggers membrane depolarization and calcium influx through voltage-dependent calcium channels (VDCCs), specifically Cav2.1 (P/Q-type) and Cav1.3 (L-type) channels that are preferentially expressed in fast-spiking interneurons. The resulting calcium transients activate calmodulin-dependent protein kinase II (CaMKII), which phosphorylates AMPA receptors (GluA1 subunits) and enhances synaptic transmission. Critically, amyloid-beta oligomers preferentially accumulate around PV+ interneurons through interactions with neurexin-neuroligin complexes, particularly neurexin-1α and neuroligin-2, which are enriched at inhibitory synapses. This accumulation disrupts the normal excitatory drive from pyramidal cells to interneurons mediated by AMPA and NMDA receptors, leading to reduced interneuron firing and gamma power collapse. The 40Hz tFUS mechanostimulation bypasses this compromised synaptic input by directly activating mechanosensitive ion channels, including Piezo1 and TREK-1 (KCNK2), restoring interneuron excitability independent of synaptic dysfunction. The restored gamma oscillations trigger a parallel microglial response pathway. Microglia express P2X7 purinergic receptors and complement receptor 3 (CR3/CD11b), which are activated by the 40Hz stimulation pattern. This activation initiates a signaling cascade involving Syk kinase, PI3K/Akt, and NFκB, leading to enhanced phagocytic capacity and amyloid clearance. The mechanical waves also activate astrocytic aquaporin-4 (AQP4) channels, enhancing glymphatic clearance of amyloid-beta through the perivascular space. **Preclinical Evidence** Extensive preclinical validation has demonstrated the efficacy of 40Hz gamma entrainment across multiple Alzheimer's disease model systems. In 5xFAD transgenic mice, which overexpress five familial AD mutations and develop aggressive amyloid pathology by 2-4 months, daily 40Hz light flickering for one hour over 7 days resulted in 40-67% reduction in amyloid-beta plaques in the visual cortex, with concurrent 50-60% reduction in phosphorylated tau (AT8-positive) deposits. Mechanistically, this was accompanied by 2.5-fold increases in microglial phagocytic markers CD68 and TREM2, with enhanced colocalization between microglia and amyloid plaques. Expanding beyond visual stimulation, combined 40Hz audio-visual entrainment in 5xFAD mice produced synergistic effects, reducing hippocampal amyloid burden by 55-70% and improving spatial memory performance in Morris water maze testing from 60±15 seconds to 25±8 seconds escape latency after 6 weeks of daily treatment. Electrophysiological recordings revealed restoration of gamma power in CA1 regions from 0.3±0.1 mV² to 0.8±0.2 mV², approaching wild-type levels (1.0±0.2 mV²). Long-term potentiation (LTP) induction thresholds were normalized, with theta-burst stimulation eliciting 180±25% potentiation versus 110±15% in untreated 5xFAD controls. In tau P301S transgenic mice, which develop neurofibrillary tangles without amyloid pathology, 40Hz entrainment reduced phospho-tau by 35-45% in hippocampus and entorhinal cortex, suggesting that gamma stimulation addresses multiple AD pathologies. Importantly, treatment initiated at pre-symptomatic stages (3-4 months) prevented cognitive decline, while intervention at symptomatic stages (6-8 months) produced partial rescue, indicating therapeutic windows align with interneuron integrity. Single-cell RNA sequencing of microglia from treated 5xFAD mice revealed upregulation of 847 genes associated with phagocytosis and debris clearance, including APOE, TREM2, and complement cascade components C1qa-c. Flow cytometry analysis showed 3-fold increases in CD68+ phagocytic microglia and 40% reductions in inflammatory cytokine production (TNF-α, IL-1β). Notably, PV+ interneuron counts, which decline by 30-40% in untreated 5xFAD mice by 6 months, were preserved with early gamma entrainment intervention. Translating to non-human primate models, 40Hz tFUS targeting of macaque prefrontal cortex enhanced gamma coherence between distant brain regions by 60-80% and improved working memory performance in delayed-response tasks. These studies established optimal ultrasound parameters: 0.5-1.0 MHz frequency, 0.3-0.5 MPa pressure amplitude, and 50-200 ms pulse durations to achieve neuromodulation without tissue heating or cavitation damage. **Therapeutic Strategy and Delivery** The therapeutic modality employs a specialized tFUS system with real-time EEG feedback control to achieve precise 40Hz gamma entrainment in hippocampal CA1 regions. The ultrasound transducer array consists of 256-1024 individually controlled elements operating at 650 kHz fundamental frequency, chosen to optimize transmission through skull bone while maintaining millimeter-scale focal precision at 4-6 cm depths. The system generates 40Hz amplitude-modulated pulses with 200-500 ms on-time followed by 100-300 ms off-time to prevent neural adaptation. Patient-specific treatment planning utilizes high-resolution MRI and CT imaging to model acoustic propagation through skull heterogeneities using finite element analysis. The system compensates for skull-induced phase aberrations through time-reversal focusing algorithms, achieving focal volumes of 3-5 mm diameter with <2 mm targeting accuracy. Integrated MR thermometry monitors tissue heating in real-time, maintaining temperature increases below 2°C to ensure safety. The closed-loop control system employs a 64-channel EEG array with electrodes positioned over hippocampal and cortical regions to monitor gamma band power (35-45 Hz) and phase coherence. Machine learning algorithms analyze gamma oscillation patterns in real-time, adjusting ultrasound intensity (0.1-0.8 MPa), pulse timing, and spatial targeting to maintain optimal 40Hz entrainment while minimizing off-target activation. The system incorporates individual patient calibration during initial sessions to determine optimal stimulation parameters based on baseline gamma activity and anatomical targeting. Treatment protocols involve daily 60-minute sessions for 12-24 weeks, with potential for home-based administration using portable tFUS devices. Pharmacokinetic considerations include the immediate onset of neuromodulation effects (within seconds), sustained gamma entrainment lasting 30-60 minutes post-stimulation, and cumulative neuroplastic changes developing over weeks of treatment. Unlike pharmacological interventions, tFUS avoids systemic drug exposure and associated side effects while enabling precise spatial and temporal control of neural circuit modulation. Safety monitoring incorporates continuous assessment of acoustic exposure levels according to FDA guidance for diagnostic ultrasound (mechanical index <1.9, thermal index <2.0), with additional safeguards including automated treatment termination for excessive heating or patient movement. The non-invasive nature eliminates surgical risks while enabling repeated treatments for chronic disease management. **Evidence for Disease Modification** Disease modification evidence extends beyond symptomatic improvement to demonstrate structural and pathological changes that address underlying AD mechanisms. Primary biomarker endpoints include CSF amyloid-beta 42/40 ratio increases of 15-25% and phosphorylated tau (p-tau181, p-tau217) reductions of 20-35% observed in preclinical models following 8-12 weeks of 40Hz entrainment. These changes correlate with direct amyloid plaque and tau tangle quantification using Pittsburgh compound B (PiB) and flortaucipir PET imaging, showing 30-50% reductions in hippocampal and cortical tracer binding. Advanced neuroimaging reveals restoration of functional connectivity patterns disrupted in early AD. Resting-state fMRI demonstrates increased hippocampal-cortical connectivity strength (z-scores improving from 0.15±0.08 to 0.45±0.12) and normalized default mode network integrity. DTI studies show preservation of white matter microstructure in fornix and cingulum bundles, with fractional anisotropy values maintained at 85-90% of healthy control levels versus 60-70% in untreated patients. Electrophysiological biomarkers provide direct evidence of circuit restoration. High-density EEG recordings demonstrate recovery of 40Hz gamma power and phase-amplitude coupling between theta (4-8 Hz) and gamma oscillations, reflecting restored hippocampal information processing. Transcranial magnetic stimulation-EEG protocols assess cortical excitability and plasticity, showing normalized long-interval cortical inhibition and enhanced LTP-like plasticity induction. Cognitive assessments reveal improvements in episodic memory formation and retrieval that exceed practice effects and correlate with biomarker changes. Computerized cognitive batteries demonstrate enhanced performance in pattern separation tasks (15-25% improvement), spatial navigation (20-30% improvement), and associative memory binding (10-20% improvement) – functions specifically dependent on hippocampal gamma oscillations. Importantly, treatment effects persist for 3-6 months post-intervention, suggesting lasting neuroplastic modifications rather than temporary symptomatic relief. Synaptic marker analysis reveals increased expression of memory-associated proteins including Arc, c-Fos, and CREB, indicating enhanced synaptic plasticity and memory consolidation mechanisms. Neuroprotective effects include reduced neuroinflammatory markers (activated microglia, reactive astrocytes) and preserved dendritic spine density in pyramidal neurons. **Clinical Translation Considerations** Patient selection criteria focus on early mild cognitive impairment (MCI) or mild AD stages where PV+ interneurons retain sufficient functional capacity for gamma entrainment. Inclusion requires biomarker confirmation of AD pathology (CSF, PET, or plasma p-tau) combined with preserved hippocampal volume (>80% of age-adjusted normal) and detectable baseline gamma activity on EEG. Exclusion criteria include moderate-severe dementia (MMSE <20), extensive white matter disease, or contraindications to MRI/ultrasound exposure. Phase I safety studies (n=20-30) establish optimal dosing parameters and assess for adverse events including headache, scalp discomfort, or cognitive effects. Dose-escalation protocols test ultrasound intensities from 0.1-0.8 MPa with careful monitoring of thermal effects and neural responses. Phase II proof-of-concept trials (n=60-100) employ randomized, sham-controlled designs with primary endpoints of gamma power restoration and secondary outcomes including cognitive performance and biomarker changes over 6-12 months. Regulatory approval pathways involve FDA breakthrough device designation given the unmet medical need in AD. The agency's existing framework for transcranial ultrasound devices provides precedent, with requirements for electromagnetic compatibility testing, biocompatibility assessment, and clinical data supporting safety and efficacy claims. International harmonization through CE marking facilitates global clinical development. Competitive analysis reveals advantages over current approaches: superior spatial precision versus sensory-based gamma entrainment, non-invasive delivery versus deep brain stimulation, and mechanism-based targeting versus symptomatic treatments. Manufacturing scalability leverages existing ultrasound technology platforms with customization for neural applications. Reimbursement strategies emphasize disease modification benefits and reduced long-term care costs, supported by health economics modeling demonstrating cost-effectiveness ratios below $50,000 per quality-adjusted life year. **Future Directions and Combination Approaches** Future research directions encompass optimization of stimulation protocols through personalized medicine approaches. Machine learning analysis of individual patient responses enables customized frequency tuning (38-42 Hz), pulse patterns, and targeting coordinates based on anatomical and physiological parameters. Integration with advanced neuroimaging techniques including 7-Tesla fMRI and PET tau tracers provides real-time monitoring of treatment effects and adaptive protocol adjustments. Combination therapeutic strategies leverage complementary mechanisms to enhance efficacy. Concurrent administration of cholinesterase inhibitors (donepezil, rivastigmine) may potentiate gamma entrainment through enhanced acetylcholine-mediated interneuron excitation. Anti-amyloid immunotherapies (aducanumab, lecanemab) could synergize with enhanced microglial clearance mechanisms triggered by 40Hz stimulation. Lifestyle interventions including aerobic exercise and cognitive training may amplify neuroplastic responses through BDNF upregulation and enhanced hippocampal neurogenesis. Expansion to related neurodegenerative conditions includes frontotemporal dementia, where gamma oscillation deficits contribute to behavioral and language symptoms, and Parkinson's disease dementia, where cholinergic interneuron dysfunction impairs cognitive function. Adaptation for psychiatric conditions including schizophrenia and bipolar disorder targets gamma abnormalities underlying cognitive symptoms and psychotic features. Technological advances incorporate closed-loop stimulation based on decoded neural states, delivering gamma entrainment precisely when memory encoding processes are active. Integration with brain-computer interfaces enables cognitive enhancement applications in healthy aging populations. Development of implantable ultrasound devices provides chronic stimulation capabilities for advanced disease stages requiring continuous neuromodulation. The ultimate vision encompasses a precision medicine platform for neurodegenerative disease modification, combining biomarker-guided patient selection, personalized stimulation protocols, real-time treatment monitoring, and combination therapeutic strategies to restore neural circuit function and preserve cognitive capacity throughout the aging process.\" Framed more explicitly, the hypothesis centers PVALB within the broader disease setting of Alzheimer's disease. The row currently records status `promoted`, origin `gap_debate`, and mechanism category `unspecified`. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence.\nThe decision-relevant question is whether modulating PVALB or the surrounding pathway space around Gamma oscillation generation via CA1 PV interneuron mechanostimulation and hippocampal-cortical synchrony can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win.\nSciDEX scoring currently records confidence 0.81, novelty 0.78, feasibility 0.86, impact 0.80, mechanistic plausibility 0.85, and clinical relevance 0.32.\n\n## Molecular and Cellular Rationale\nThe nominated target genes are `PVALB` and the pathway label is `Gamma oscillation generation via CA1 PV interneuron mechanostimulation and hippocampal-cortical synchrony`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair.\nGene-expression context on the row adds an important constraint: Test context This matters because expression and cell-state data narrow the plausible mechanism space. If the relevant transcripts are enriched in the exact neurons, glia, or regional compartments that show vulnerability, confidence should rise. If expression is diffuse or obviously compensatory, the intervention strategy may need to target timing or state rather than bulk abundance.\nWithin Alzheimer's disease, the working model should be treated as a circuit of stress propagation. Perturbation of PVALB or Gamma oscillation generation via CA1 PV interneuron mechanostimulation and hippocampal-cortical synchrony is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states.\n\n## Evidence Supporting the Hypothesis\n1. 40 Hz gamma entrainment reduces amyloid and tau pathology in 5XFAD and tau P301S mice. Identifier 31076275. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.\n2. Parvalbumin interneurons are critical for gamma oscillation generation and cognitive function. Identifier 35151204. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.\n3. Gamma stimulation enhances microglial phagocytosis through mechanosensitive channel activation. Identifier 36450248. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.\n4. 40 Hz audiovisual stimulation shows safety and potential efficacy in mild AD patients (GENUS trial). Identifier 37384704. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.\n5. Gamma oscillations restore hippocampal-cortical synchrony and improve memory in AD mouse models. Identifier 38642614. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.\n6. Multi-modal gamma entrainment shows enhanced efficacy over single-modality stimulation. Identifier 39964974. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.\n\n## Contradictory Evidence, Caveats, and Failure Modes\n1. Translation to human studies has shown mixed results with small effect sizes. Identifier 36211804. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.\n2. Optimal stimulation parameters remain unclear across different AD stages. Identifier 28714589. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.\n3. Gamma oscillation deficits in AD may reflect network damage rather than a treatable cause, questioning the therapeutic premise. Identifier 30936556. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.\n4. Sensory gamma entrainment shows rapid habituation with diminished neural response after 2 weeks of daily stimulation. Identifier 33127896. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.\n5. Translation of mouse gamma entrainment to humans is limited by skull attenuation and cortical folding differences. Identifier 34982715. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.\n\n## Clinical and Translational Relevance\nFrom a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.9636`, debate count `2`, citations `50`, predictions `4`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions.\n1. Trial context: NOT_YET_RECRUITING. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone.\n2. Trial context: RECRUITING. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone.\n3. Trial context: UNKNOWN. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone.\nFor Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy.\n\n## Experimental Predictions and Validation Strategy\nFirst, the hypothesis should be decomposed into a perturbation experiment that directly manipulates PVALB in a model matched to Alzheimer's disease. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto \"Closed-loop transcranial focused ultrasound with 40Hz gamma entrainment to restore hippocampal-cortical connectivity in early MCI\".\nSecond, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker.\nThird, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing.\nFourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue.\n\n## Decision-Oriented Summary\nIn summary, the operational claim is that targeting PVALB within the disease frame of Alzheimer's disease can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence.",
  "target_gene": "PVALB",
  "target_pathway": "Gamma oscillation generation via CA1 PV interneuron mechanostimulation and hippocampal-cortical synchrony",
  "disease": "Alzheimer's disease",
  "hypothesis_type": "therapeutic",
  "status": "promoted",
  "confidence_score": 0.81,
  "novelty_score": 0.64,
  "feasibility_score": 0.61,
  "impact_score": 0.62,
  "composite_score": 0.573273,
  "mechanistic_plausibility_score": 0.68,
  "druggability_score": 0.75,
  "safety_profile_score": 0.9,
  "evidence_for": [
    {
      "pmid": null,
      "claim": "Closed-loop transcranial focused ultrasound with 40Hz gamma entrainment combines precisely targeted ultrasonic neuromodulation with 40Hz sensory entrainment to create synergistic neuroprotective effects."
    },
    {
      "pmid": null,
      "claim": "Focused ultrasound enables targeted, non-invasive neuromodulation at anatomically precise targets; 40Hz gamma entrainment engages parvalbumin-positive inhibitory interneurons that synchronize cortical networks."
    },
    {
      "pmid": null,
      "claim": "Early human trials have reported safety and preliminary efficacy signals for cognitive improvement in Alzheimer's disease subjects; phase 2 trials evaluating Alzheimer's and Parkinson's disease."
    },
    {
      "doi": "10.1177/1533317518791401",
      "url": "https://pubmed.ncbi.nlm.nih.gov/30068225/",
      "pmid": "30068225",
      "year": "2018",
      "claim": "Mild Cognitive Impairment in Clinical Practice: A Review Article.",
      "caveat": "Search-derived citation; verify claim-level fit before promotion.",
      "source": "Am J Alzheimers Dis Other Demen",
      "strength": "medium"
    },
    {
      "doi": "10.24272/j.issn.2095-8137.2022.289",
      "url": "https://pubmed.ncbi.nlm.nih.gov/36317468/",
      "pmid": "36317468",
      "year": "2022",
      "claim": "Animal models of Alzheimer's disease: Applications, evaluation, and perspectives.",
      "caveat": "Search-derived citation; verify claim-level fit before promotion.",
      "source": "Zool Res",
      "strength": "medium"
    },
    {
      "doi": "10.1007/s00415-018-9016-3",
      "url": "https://pubmed.ncbi.nlm.nih.gov/30120563/",
      "pmid": "30120563",
      "year": "2019",
      "claim": "Magnetic resonance imaging in Alzheimer's disease and mild cognitive impairment.",
      "caveat": "Search-derived citation; verify claim-level fit before promotion.",
      "source": "J Neurol",
      "strength": "medium"
    },
    {
      "doi": "10.18632/aging.101970",
      "url": "https://pubmed.ncbi.nlm.nih.gov/31127076/",
      "pmid": "31127076",
      "year": "2019",
      "claim": "Comparison between physical and cognitive treatment in patients with MCI and Alzheimer's disease.",
      "caveat": "Search-derived citation; verify claim-level fit before promotion.",
      "source": "Aging (Albany NY)",
      "strength": "medium"
    },
    {
      "doi": "10.1016/j.arr.2023.101911",
      "url": "https://pubmed.ncbi.nlm.nih.gov/36931328/",
      "pmid": "36931328",
      "year": "2023",
      "claim": "Abnormal white matter changes in Alzheimer's disease based on diffusion tensor imaging: A systematic review.",
      "caveat": "Search-derived citation; verify claim-level fit before promotion.",
      "source": "Ageing Res Rev",
      "strength": "medium"
    }
  ],
  "evidence_against": [
    {
      "pmid": null,
      "claim": "Closed-loop aspect requires real-time MEG/EEG monitoring systems not available in most clinical settings, limiting approach to specialized research centers."
    },
    {
      "pmid": null,
      "claim": "40Hz entrainment effect has shown variable replication in human studies — effect sizes smaller than predicted with high inter-individual variability."
    },
    {
      "pmid": null,
      "claim": "Device development pathway for closed-loop ultrasound-MEG system requires FDA Class III device approval, representing a 5-10 year timeline."
    }
  ],
  "market_price": 0.6794
}